anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a Qizhen capsule and a preparation method thereof, particularly to auxiliary medicine for treating tumors. The Qizhen capsule comprises the components with the following proportion by weight: 9.2% to 13.8% of pearl, 39% to 57% of astragalus root, 7.2% to 10.8% of notoginseng, 14.4% to 21.6% of dyers woad leaf and 10.8% to 16.2% of pairs root. The present invention also provides a preparation method for the Qizhen capsule. Prepared Qizhen capsules have the functions for benefiting qi, removing blood stasis and clearing away heat and toxic materials to human bodies, improve the qi vacuity and the blood stasis to tumor patients and the blood stasis for transforming into heat, enhance the immunological functions, the life quality and the weight, and protect white cells. The Qizhen capsule has the advantages of safety, no toxic or side effect and low cost. The Qizhen capsule can be suitable for the auxiliary treatment for the chemotherapy of tumor patients, such as lung cancer patients, mammary cancer patients, stomach cancer patients, etc., and the Qizhen capsule is novel safe and effective Chinese medicine.
PROBLEM TO BE SOLVED: To produce a carcinogenic preventing agent or a carcinostatic agent having high safety at a low cost by including a specific compound made from ferulic acid derived from a natural product as a raw material as an active ingredient. SOLUTION: This carcinogenic preventing agent or a carcinostatic agent is obtained by including a compound represented by formula I (R1 is a 1-11C alkyl; and (n) is 1-3) as an active ingredient. The above compound is capable of producing especially an ultrahigh proliferation suppressing activity against a precancerous cell or an early cancerous cell and can be used by either of oral and parenteral administrations. For example, the above active ingredient is preferably administered in a daily dose of 20-2,000 mg/kg body weight in the case of oral or rectal administrations and 20-200 mg/kg body when used as a parenteral injection.  The compound represented by formula I is a new compound and is obtained by reacting a compound represented by formula II with a compound represented by formula III (X is a halogen or a substituted sulfonyloxy) in an organic solvent in the presence of a metal hydride (e.g. lithium hydride).
Proteins from fish or marine invertebrates, freed from the phosphatide fraction and comminuted to a fibrous fluffy structure are treated with aqs. solns. of acid e.g. CH3CH(OH)COOH or HCl at a concn. suitable to catalyse the swelling power of the starting material in order to obtain a protein gel for use in foodstuffs, pharmaceuticals, dietetics and cosmetics. After completed swelling the pH of the medium is raised to that of the natural starting material by washing with H2O or aqs. solns. and finally removing excess water.
Study Group (n= 20) was recieved Temporomandibular joint ve soft tissue techniques. The techniques were applied 30 minutes once a week for 4 weeks by physiotherapist to the study group.
This is a first in human, open-label, multicenter, Phase I/Ib trial of AVID200. To date, there is no therapy for MF evaluated in the clinic that clearly demonstrates the ability to target the malignant HSC and result in effective and reproducible bone marrow morphologic, cytogenetic and molecular responses. Medicinal therapies that result in disease course modification are urgently needed in this chronic and progressive myeloid malignancy. TGF-β likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. The study team proposes that inhibiting the TGF-β signaling pathway in MF will decrease the fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation and restore normal hematopoiesis. AVID200 is a fusion protein containing TGF-β receptor ectodomains fused to a human Fc IgG domain. AVID200 is a potent TGFβ trap with antibody-like properties which has pM potency against two of the three TGFβ ligands, TGFβ1 and β3.
ADPKD is characterized by progressive cyst formation and enlargement leading to kidney failure. Tolvaptan is currently the only FDA-approved treatment for ADPKD; however, it can cause serious adverse effects including hepatotoxicity. There remains an unmet clinical need for effective and safe treatments for ADPKD. The extracellular Ca2+-sensing receptor (CaSR) is a regulator of epithelial ion transport. FDA-approved CaSR activator cinacalcet can reduce cAMP-induced Cl- and fluid secretion in various epithelial cells by activating phosphodiesterases (PDE) that hydrolyze cAMP. Since elevated cAMP is a key mechanism of ADPKD progression by promoting cell proliferation, cyst formation and enlargement (via Cl- and fluid secretion), here we tested efficacy of cinacalcet in cell and animal models of ADPKD. Cinacalcet treatment reduced cAMP-induced Cl- secretion and CFTR activity in MDCK cells as suggested by ∼70 % lower short-circuit current (Isc) changes in response to forskolin and CFTRinh-172, respectively. Cinacalcet treatment inhibited forskolin-induced cAMP elevation by 60 % in MDCK cells, and its effect was completely reversed by IBMX (PDE inhibitor). In MDCK cells treated with forskolin, cinacalcet treatment concentration-dependently reduced cell proliferation, cyst formation and cyst enlargement by up to 50 % without affecting cell viability. Cinacalcet treatment (20 mg/kg/day for 7 days, subcutaneous) reduced renal cyst index in a mouse model of ADPKD (Pkd1flox/flox;Ksp-Cre) by 20 %. Lastly, cinacalcet treatment reduced cyst enlargement and cell proliferation in human ADPKD cells by 60 %. Considering its efficacy as shown here, and favorable safety profile including extensive post-approval data, cinacalcet can be repurposed as a novel ADPKD treatment.
Cases of hepatitis and clinically significant liver dysfunction were observed in association with VIVITROL exposure during the clinical development program and in the postmarketing period. Transient, asymptomatic hepatic transaminase elevations were also observed in the clinical trials and postmarketing period. Although patients with clinically significant liver disease were not systematically studied, clinical trials did include patients with asymptomatic viral hepatitis infections. When patients presented with elevated transaminases, there were often other potential causative or contributory etiologies identified, including pre-existing alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other potentially hepatotoxic drugs. Although clinically significant liver dysfunction is not typically recognized as a manifestation of opioid withdrawal, opioid withdrawal that is precipitated abruptly may lead to systemic sequelae including acute liver injury. 

Patients should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms of acute hepatitis. Use of VIVITROL should be discontinued in the event of symptoms and/or signs of acute hepatitis.
FIELD: agriculture, veterinary science. SUBSTANCE: method involves administration to calves the probiotic "RAS" obtained on the basis of culture Bacillus subtilis by method of genetic recombinations. Probiotic is given to animals by oral route at the dose 1-4 ml/head, once per a day before morning feeding for 10 days. Method can be used for normalization of growth and development of newborn calves, enhancement of biological tone and resistance to diseases in the early age. EFFECT: improved method of breeding. 2 cl, 1 tbl, 2 ex
Major Depressive Disorder (MDD) is a lifelong and recurrent illness, such that many individuals require multiple courses of antidepressant medication treatment. While some patients respond completely to each course of treatment, many do not, and with each unsuccessful antidepressant trial the likelihood that a patient will respond decreases. This raises the possibility that neurophysiologic response in subsequent antidepressant treatment may be influenced by learning processes including sensitization, habituation, and/or classical conditioning. Classical conditioning would entail the association of cues such as pill-taking (conditioned stimuli; CS) with the effects of active medication (unconditioned stimulus; US), such that later presentation of the CS alone would come to elicit a conditioned response (CR). Such effects could be revealed by blinded administration of placebo following a period of treatment with active medication. Habituation effects (tolerance), or sensitization effects (increased response), which require only repeated exposure to a stimulus, might be evidenced after repeated courses of antidepressant treatment. Knowledge of how learning processes impact neurophysiologic response to successive courses of antidepressant treatment would have relevance for clinical populations. Specific hypotheses, however, may be tested in healthy non-clinical samples to avoid potential confounding factors related to severity or chronicity of illness. Learning theories would suggest two hypotheses: (1) neurophysiologic response to placebo will differ between subjects who were previously treated with antidepressant treatment as compared to placebo (classical conditioning hypothesis); and (2) neurophysiologic response to an initial course of antidepressant treatment will differ from response to a repeated course of antidepressant treatment.
CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 150mg.
BACKGROUND: This systematic review and meta-analysis aimed to inventory all outcome measures that are affected by tapering in chronic noncancer pain and to investigate the effectiveness of tapering.
METHODS: A literature search was conducted from inception to April 2024 in MEDLINE via PubMed, Web of Science, SCOPUS, EMBASE, and PsycINFO.
RESULTS: The initial database search identified 3969 articles, which were screened by two independent reviewers. Studies evaluating pain medication tapering in adults with chronic noncancer pain were eligible for inclusion. In total, 57 and 34 articles were included in the systematic review and meta-analysis, respectively. Risk of bias assessment demonstrated poor, fair, and good quality in 30, 24, and three studies, respectively. Pain intensity was the most reported outcome measure, as reported in 28 studies. Furthermore, a random-effect three-level meta-analysis was performed. An overall effect size of 0.917 (95% confidence interval 0.61-1.22; P<0.001) was found, indicating a beneficial effect of tapering. In addition, a statistically significant improvement was demonstrated after tapering for pain intensity, headache disability, the number of headache days per month, anxiety, depression, the number of pills consumed per month, the number of days with medication intake per month, pain catastrophising, and pain interference. No statistically significant effect was observed for physical functioning, mental health-related quality of life, opioid use, pain self-efficacy, and physical health-related quality of life.
CONCLUSIONS: This systematic review revealed a broad range of outcome measures affected by tapering. Owing to the high risk of bias of the included articles, the results of this meta-analysis must be interpreted with caution.
SYSTEMATIC REVIEW PROTOCOL: CRD42023416343 (PROSPERO).
One FDG-PET/CT prior to 1st cycle of chemotherapy; 1 FDG-PET/CT after the 1st cycle of chemotherapy; 1 optional FDG-PET/CT after the 2nd cycle of chemotherapy. All three with optional volumetric CT scans.
BACKGROUND: Patellar fracture is a common injury caused by overstrain of the extensor mechanism or a direct trauma to the knee. The most common complications after patellar fracture are nonunion, infection, post-traumatic arthritis, joint fibrosis, symptomatic hardware, and extensor mechanism failure. These are attributed to the post-fracture flexion and extension movements, the primary damage to the articular cartilage, and the thin soft tissue coverage over the knee. To our knowledge, prepatellar bursa mucosa is an unreported postoperative complication of patellar fracture.
METHODS: We describe a case of a 58-year-old woman with a left patellar fracture from a fall. Complete healing was achieved after in 2 months postoperatively using the improved Kirschner wire tension band and a cable grip system; however, at 7 months postoperatively, a prepatellar skin mass appeared. The patient reported prepatellar discomfort with no pain and influence of movement of the knee and daily life. One year postoperatively, we surgically removed the implants and mass. The pathological result showed bursa mucosa.
RESULTS: The literature review shows that pain, secondary knee dysfunction, fracture nonunion, and malunion are postoperative complications of patellar fractures. However, prepatellar bursa mucosa have not been previously reported as a postoperative complication.
CONCLUSION: This case highlights the need for appropriate placement of the intraoperative implant in adults with patellar fractures.
A reusable sorbent, and method of use, for carbon dioxide capture and purification. The sorbent comprises pelletized composites for use in a fluidized bed process, each pellet comprising calcium oxide; an aluminate binder; and at least one transition metal component. The aluminate binder is preferably calcium aluminate or bauxite, and the transition metal is preferably selected from copper, manganese and cobalt. For carbon dioxide capture, the transition metal is an oxide, which has an exothermic reduction reaction. For removal of oxygen from carbon dioxide, the transition metal in the pellets is non-oxidized. Reduction of the oxygen carrier can be performed by providing a flow of fuel gas, such as methane. The pelletized composites provide for improved carbon dioxide capture and longer use of the sorbents with significant mitigation of decay, and without the disadvantages of oxy-firing.
It is well established that the preoperative nutritional status of gastric cancer (GC) patients significantly affects the prognosis of the operated patients, their overall survival, as well as the disease-specific survival. Existing data support that preoperative assessment of nutritional status and early correction of nutritional deficiencies exert a favorable effect on early postoperative outcomes. A variety of relevant indices are used to assess the nutritional status of GC patients who are candidates for surgery. The guidelines of almost all international organizations recommend the use of oral enteral nutrition (EN). Oncologically acceptable types of gastrectomy and methods of patient rehabilitation should take into account the expected postoperative nutritional status. The majority of data support that perioperative EN reduces complications and hospital stay, but not mortality. Oral EN in the postoperative period, albeit in small amounts, helps to reduce the weight loss that is a consequence of gastrectomy. Iron deficiency with or without anemia and low serum levels of vitamin B12 are common metabolic sequelae after gastrectomy and should be restored. EN also significantly helps patients undergoing neoadjuvant or adjuvant antineoplastic therapy. The occurrence of the so-called "postgastrectomy syndromes" requires dietary modifications and drug support. This review attempts to highlight the benefits of EN in GC patients undergoing gastrectomy and to emphasize the type of necessary nutritional management, based on current literature data.
The invention discloses a Chinese medicine bath with effects of clearing liver-heat and regulating menstruation. The Chinese medicine bath is mainly prepared from the following raw materials in parts by weight: 6-9 parts of madder, 8-16 parts of silybum marianum, 8-12 parts of agrimonia pilosa, 9-15 parts of (fried) sanguisorba officinalis, 5-10 parts of charred folium artemisiae argyi, 5-9 parts of picrasma quassioses, 10-20 parts of rhizoma anemarrhenae, 10-20 parts of herba taxilli, 9-18 parts of trichosanthes kirilowii maxim, 10-15 parts of eclipta prostrate, 6-9 parts of concha haliotidis, 8-16 parts of (stir-fried with wine) dipsacales, 10-20 parts of leonurus artemisia and 15-20 parts of eucommia ulmoides oliver. The Chinese medicine bath has effects of tonifying liver, nourishing kidney, clearing heat, activating blood, stopping bleeding and relieving pain and can effectively regulate the body function of females and enhance the body immunity. The Chinese medicine bath can enter the body through the skin or the pudendum, the side effects of drugs on the human body are reduced, the treatment is safe, and the curative effect is reliable. Through clinical verifications, the Chinese medicine bath has the advantages of being significant in curative effect, quickly becoming effect, safe and reliable. People can rest assured to use the Chinese medicine bath.
BACKGROUND: LV geometry with shape index (SI) and eccentricity index (EI) measured by myocardial perfusion positron emission tomography/computed tomography (PET/CT) may allow the evaluation of left ventricular (LV) adverse remodeling. This first study aims to explore the relationship of SI and EI values acquired by Nitrogen-13 ammonia PET/CT in patients with normal perfusion, ischemia, and myocardial infarction. And evaluate the correlations between the variables of LV geometry, and with the variables of LV function.
METHODS AND RESULTS: One hundred and forty patients who underwent an electrocardiogram (ECG)-gated PET/CT were selected and classified into 4 groups according to ischemia or infarction burden (normal perfusion, mild ischemia, moderate-severe ischemia, and infarction). The variables were automatically retrieved using dedicated software (QPS/QGS; Cedars-Sinai, Los Angeles, CA, USA). On multicomparison analysis (one-way ANOVA and Dunnett's Test), subjects in the infarction group had significant higher values of SI end-diastolic rest (P < 0.001), and stress (P = 0.003), SI end-systolic rest (P = 0.002) and stress (P < 0.001) as well as statistically significant lower values of EI rest (P < 0.001) and stress (P < 0.001) when compared with all other groups. Regarding Pearson correlation, in the infarcted group all the variables of SI and EI were significantly correlated (P < 0.001) with strong correlation coefficients (>0.60). SI end-systolic correlated significantly with the variables of LV function independently of the group of patients (P < 0.05).
CONCLUSIONS: Shape and eccentricity indices differ in patients with myocardial infarction as compared to patients with ischemia or normal perfusion. This encourage further research in their potential for detecting LV adverse remodeling.
The mobile-APP based CBT-I consists of 6 weekly session. The treatment is structured and based on the well-established CBT elements for treating insomnia. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention. reminders and individualized feedback regarding the behavioral strategies will be sent to the participant every week.
Store ADLARITY in the refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze. Allow the pouch to reach room temperature before opening and removing the new transdermal system for application [see Dosage and Administration (2.3)]. Keep ADLARITY in the individually sealed pouch until use. Used transdermal systems should be folded with the adhesive surfaces pressed together and discarded in the trash. Do not flush used transdermal systems down the toilet.
Although access to antiretroviral therapy has led to increased survival among people living with HIV (PWH) in Africa, this population now has higher cardiovascular disease (CVD) - mortality than the general population largely due to an increased burden of hypertension. In Nigeria, the acute shortage of physicians limits the capacity to control hypertension among PWH at the primary care level where the majority receive treatment. This study proposes the use of practice facilitation (PF) - which will provide external expertise on practice redesign and a tailored approach to delivery of the evidence-based task strengthening strategy - to integrate hypertension into the HIV care model. Using a clinical-effectiveness implementation design, we will evaluate the effect of a PF strategy for integrating an evidence-based intervention for hypertension (HTN) control into HIV care among 960 patients with uncontrolled HTN in 30 primary health centers (PHCs) in Nigeria. Study is in 3 phases: 1) a pre-implementation phase that will develop a tailored PF intervention for integrating TASSH into HIV clinics; 2) an implementation phase that will compare the clinical effectiveness of PF vs. a self-directed condition (receipt of information on TASSH without PF) on BP reduction; and 3) a post- implementation phase to evaluate the effect of PF vs. self-directed condition on the adoption and sustainability of TASSH. The PF intervention comprises: (a) an advisory board to provide leadership support for implementing TASSH in HIV clinics; (b) training of the HIV nurses on TASSH protocol; and (c) training of practice facilitators, who will serve as coaches, provide support, and performance feedback to the HIV nurses